Links | 2017 | 2016 | 2015 | 2014 | 2013 | Selected Publications



ORCID (Open Researcher and Contributor ID):ID 0000-0003-4619-9660




Tenenbaum L. and Humbert-Claude M. (2017). Glial cell line-Derived Neurotrophic Factor gene delivery in Parkinson’s disease: a delicate balance between neuroprotection, trophic effects and unwanted compensatory mechanisms. Front. Neuroanat. doi: 10.3389/fnana.2017.00029

Liu, S., Sandner, B., Schackel, T., Nicholson, L., Chtarto, A., Tenenbaum, L., Puttagunta, R., Müller, R., Weidner, R., Blesch, A. (2017). Regulated Viral BDNF Delivery in Combination with Schwann Cells Promotes Axonal Regeneration through Capillary Alginate Hydrogels after Spinal Cord Injury. Acta Biomaterialia. (In Press)



Barroso-Chinea P., Cruz-Muros I., Afonso-Oramas D., Castro-Hernández J., Salas-Hernández J., Chtarto A., Luis-Ravelo D., Humbert-Claude M., Tenenbaum L. and González-Hernández T. (2016).
Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system. Neurobiol. Dis. 88 : 44–54.

Chtarto A,  Humbert-Claude M and Bockstael O, Das AT, Boutry S, Breger L, Barroso-Chinea P, Klaver B, Melas C, González-Hernández T, Müller R, DeWitte O, Levivier M, Lundberg C, Berkhout B, and Tenenbaum L . (2016) A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.  Mol. Ther. Methods and Clin. Dev.. 5, 16027; doi:10.1038.

Das A.T., Tenenbaum L., and Berkhout B. (2016). Tet-On systems for doxycycline-inducible gene expression. Curr Gene Ther. 16:156-67.

Bazewicz,M., Draganova,D., Makhoula, M, Chtarto,A., Elmaleh,V, Tenenbaum,L., Caspers,L., Bruyns,C., Willermain,F. (2016). Effect of SOCS1 overexpression on RPE cell activation by proinflammatory cytokines. Neuroscience Letters 630:209–215.

Humbert-Claude M, Duc D, Dwir D, Thieren L, Sandström von Tobel J, Begka C, Legueux F, Velin D, Maillard MH, Do KQ, Monnet-Tschudi F, Tenenbaum L. (2016). Tollip, an early regulator of the acute inflammatory response in the substantia nigra. J Neuroinflammation: 13(1):303.



Hanna-El-Daher, L., Béard, E., Henry, H., Tenenbaum, L. and Braissant, O. (2015). Mild elevation of guanidinoacetate under partial GAMT deficiency strongly affects brain cell development. Neurobiol. Dis. 79 :14-27



Ayuso E, Blouin V, Lock M, McGorray S, Alvira MR., Auricchio A,  Bosch F, Bucher S, Chtarto A,  Clark KR, Darmon C, Doria M, Fountain W, Gao G, Giacca M, Kleinschmidt J, Leon X, Leuchs B, Mizukami H, Normand Y, Ozawa K, Surosky R, Tenenbaum L, Van Linden I, Weins B, Wright JF, Zelenaia O, Zentilin L, Snyder  RO and Moullier P. (2014). Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material.  Hum Gene Ther. 25(11):977-87.

Bockstael O, Tenenbaum L, Dalkara D, Melas C, De Witte O, Levivier M, Chtarto A. (2014). Intracisternal delivery of NFκB-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment. Front Mol Neurosci. 2014;7:92.



Chtarto, A., Bockstael, O., Tshibangu, T., Dewitte, O., Levivier, M. and Tenenbaum, L. (2013). A next step in adeno-associated virus (AAV)- mediated gene therapy for neurological diseases: Regulation and targeting. British Journal of Clinical Pharmacology 76: 217–232

Chtarto, A., Bockstael, O., Gebara, E., Vermoesen, K., Melas, C., Pythoud, C., Levivier, M., Dewitte, O., Luthi-Carter, R., Clinkers, R. and Tenenbaum L. (2013). An adeno-associated virus-based intracellular sensor of pathological Nuclear Factor-kappa B activation for disease-inducible gene transfer. PlosOne 2013;8(1):e53156

Dismuke, D.J., Tenenbaum, L., Samulski, R.J. (2013). Biosafety of Recombinant Adeno-associated Virus Vectors. Curr Gene Ther. 13: 434-452


Selected Publications

Tenenbaum L. , J.L.Darling and E.Hooghe-Peters (1994). Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the central nervous system. Gene Ther, vol.1, suppl.1,80.

Tenenbaum L., F.Jurysta, A.Stathopoulos, Z.Puschban, C.Melas, W.T.J.M.C. Hermens, J.Verhaagen, B.Pichon, T.Velu and M.Levivier. (2000). Tropism of AAV-2 vectors for neurons of the globus pallidus. NeuroReport, 11,2277-2283.

Tenenbaum L., A. Chtarto, E. Lehtonen, D. Blum , V. Baekelandt, T.Velu, J.Brotchi and M. Levivier (2002). Neuroprotective Gene Therapy for Parkinson’s disease. Curr. Gene Ther. 2, 451-483.

Chtarto A., H.U.Bender, C.O.Hanemann, T.Kemp, E.Lehtonen, M. Levivier , J. Brotchi, T.Velu and L. Tenenbaum (2003. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther. 10, 86-96.

L.Tenenbaum, E.Lehtonen and P.Monahan. (2003). Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. 3: 545-565.

Tenenbaum L., A. Chtarto, E. Lehtonen, T.Velu, J.Brotchi and M. Levivier (2004). Recombinant AAV-mediated gene delivery to the Central Nervous System. J. Gene Med. 6 Suppl 1:S212-22.

Tenenbaum L., M. Peschanski, C.Melas F.Rodesh, E.Lehtonen, A.Stathopoulos, A.Chtarto, T. Velu, J.Brotchi and M. Levivier (2004). Efficient early and sustained transduction of human fetal mesencephalon using AAV2 vectors. Cell Transplant 13, 565-571.



CHUV - Pavillon 3 - Avenue de Beaumont - CH-1011 Lausanne
Tel. +41 21 314 21 20
Fax +41 21 314 08 24